APR-APPLIED-PHARMA
APR Applied Pharma Research s.a. - the Swiss independent developer of science driven patented healthcare products - and MONRONE FZC Healthcare (Monrone), the middle east Outsourcing Health and Beauty business, have recently announced they have entered a partnership agreement to promote, distribute and market the Halykoo pediatric healthcare product line in Qatar, Kuwait, United Arab Emirates, Saudi Arabia, Oman, Bahrain.
Halykoo is a global umbrella brand of pediatric OTC products conceived and developed by the Switzerland based company. Halykoo innovative portfolio includes 12 different products spanning four major therapeutic areas such as skin care, cough & cold, eye, ear & mouth and nutraceutical. They all rely on formulations and delivery systems specifically tailored to match babies and children different needs throughout each stage of their growth.
This partnership will allow Monrone to accomplish its transition towards becoming an established pharmaceutical company within the Middle East countries offering high quality, innovative and branded products dedicated to infants and children, such as Halykoo.
“We believe our partnership with APR is an opportunity to successfully gain a sizable share of the competitive paediatric healthcare market which, in the middle east region is worth up to 120 million $. We believe Halykoo provides problem solution products offering parents a simple, safe and innovative range of goods to deal with their babies healthcare issues. – comments Mohamed Samir – Market access manager, MONRONE FZC - We have worked hard to be recognized as a highly dynamic yet very caring provider in the market of OTC products: the innovative products within the Halykoo line, are able to set a new pace in the pediatric healthcare market while providing added value to our partners in full compliance with our company’s commitment for the future.”
The deal between APR and MONRONE comes after previous marketing of Halykoo in Italy, Ukraine and the former Yugoslavia area, and thanks to this agreement APR will we able to introduce its brand also in the pediatric care market of many country of the Middle East, further expanding its network distribution across the world and confirming the strong appeal and distinctive positioning of Halykoo on an international scale.
Paolo Galfetti, CEO and Co-Founder of APR, explained: “Providing parents worldwide with products that meet the specific needs of their children over the first six years of their lives, Halykoo line offers the unique opportunity to face the high consumer turnover given by babies ageing out of the category. We are proud to welcome MONRONE in our growing global network partners and strongly believe it will be an important partner for us as it holds the experience, the geographic reach and distribution infrastructure to best market and deliver Halykoo product range.” he added.
About Halykoo
Halykoo is a new global brand in the pediatric OTC market, conceived and developed by APR starting from an unmet demand driven insight, which aims to transform the moments of child healthcare in a time of relation (between mother and kid) peaceful, simple and safe in order to get parents’ confidence and smiling babies.
Halykoo is the first and only OTC pediatric healthcare brand that matches formulations specifically focused on each of the unique ages and stages of children’s growth, since birth, with smart and innovative formulations and delivery systems intended to simplify their use for parents and reduce the hassle for babies.
Halykoo products are the perfect combination of Swiss, high-quality research combined with an extensive understanding of child and caregivers needs: as a result, each Halykoo product provides the right formula – from accurate selection of the ingredients (including natural organic certified components), to careful dosing of the ingredients and full compliance with the strictest safety standards – and the right delivery system for the right age.
For more info about Halykoo, please visit: www.halykoo.com
About MONRONE Healthcare
Founded in 2012, the vision of MONRONE Healthcare. MONRONE is to become a ”widely respected regional & international Healthcare company” by advancing its mission of “persisting in Nutraceutical innovation for the benefit of human beings.” It focuses on constant improving, creating products through partnership with world class R&D laboratories that match the ever-changing lifestyles and needs of people and families everywhere. To date, over 44 of the company's products have been commercializing across the Middle-east, and over 600,000 patient leveraging these products, Monrone recognized as the most highly dynamics provider of over-the-counter products in Middle-east yet nimble enough to give detailed attention to each and every one of their products .To learn more about MONRONE, please visit us http://www.monrone.org
About APR Applied Pharma Research s.a.
APR is an independent Swiss company, specialized in the development of science-driven, patent-protected healthcare products. The Company identifies, develops and licenses science- driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on 2 (two) major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering value-added, R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue-generating branded products marketed in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis. For more info, please visit: www.apr.ch .
View source version on businesswire.com: http://www.businesswire.com/news/home/20161212005433/en/
Contact:
APR Applied Pharma Research s.a.
Paolo Galfetti, T: +41 91
6957020
Chief Executive Officer
paolo.galfetti@apr.ch
or
Havas
PR Milan - Press Office APR Applied Pharma Research s.a.
Sara
Bernabovi, T: +39 02 85457032
sara.bernabovi@havaspr.com
or
MONRONE
FZC.
Sharjah - UAE
Farag Ibrahim, T: +971 67428215
CEO
ceo@monrone.org
or
MONRONE
HEALTHCARE LLC. Monrone affiliate
Dubai – UAE
Mohamed
Saad, T: +971 509923301
Business Unit Manager
m.saad@monrone.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 11:17:00 CEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom